Clinical Pharmacology Studies. Phase 1

reportActive / Technical Report | Accession Number: ADA210900 | Open PDF

Abstract:

In this report we summarize the work on four different oral formulations of pyridostigmine. We believe that our familiarity with the pharmacokinetics and pharmacodynamics of pyridostigmine has enhanced the validity of our observations. We also describe a study of the safety and tolerance of multiple once-daily doses of WR 6026 in a placebo-controlled, double-blind study. We are convinced that this study design was essential for correctly interpreting symptoms and abnormalities of laboratory tests that would have been impossible without a placebo control group. Keywords Antimalarials.

Author(s):
Lietman, Paul S. ; Petty, Brent G. ; Kornhauser, David M.
Author Organization(s):
JOHNS HOPKINS UNIV BALTIMORE MD DIV OF CLINICAL PHARMACOLOGY
Descriptive Note:
Annual rept. 9 Mar 1988-8 Mar 1989
Supplementary Note:
DOI: 10.21236/ADA210900
Pagination:
0023

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Contract/Grant Number(s):
DAMD17-85-C-5133
Monitor Series:
USAMRDC
 Subject Terms
Joint Capability Areas:
JCA_5_Command and Control; JCA_5.5.2_Task; JCA_5.5_Direct; JCA_6_Net Centric; JCA_1_Force Support; JCA_6.1_Information Transport; JCA_1.2_Force Preparation; JCA_1.2.3_Educating; JCA_5.3_Planning; JCA_5.2_Understand; JCA_5.2.3_Share Knowledge and Situational Awareness; JCA_8_Building Partnerships; JCA_1.4.1_Force Health Protection; JCA_1.4_Force Support; JCA_6.2.3_Core Enterprise Services; JCA_8.2_Shape; JCA_1.2.5_Lessons Learned; JCA_4.5.4_Requirements Definition; JCA_4.5_Operational Contract Support
Communities of Interest:
Biomedical
Descriptor(s):
*ANTIMALARIALS, *PHARMACOKINETICS, CLINICAL MEDICINE, SIGNS AND SYMPTOMS, PLACEBOS, ABNORMALITIES, PHARMACOLOGY, LABORATORY TESTS, CONTROL, SAFETY
Field(s)/Group(s):
Pharmacology
Keyword(s):
PYRIDOSTIGMINE
Report Date:
1989 Apr 21